Vincent Ho, MD
Enriched profileDirector of Clinical Operations, Stem Cell Transplantation; Institute Physician; Professor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute
Vincent Ho is Director of Clinical Operations, Stem Cell Transplantation; Institute Physician; Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 667 publications with 27,406 citations (h-index 86); ClinicalTrials.gov lists 12 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Vincent T. Ho, MD, is Director of Clinical Operations, Stem Cell Transplantation at Dana-Farber Cancer Institute. The public record shows 667 publications with 27,406 citations (h-index 86), centered on Multiple Myeloma, MDS / MPN, Lymphoma. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 8 companies, 2 NIH-funded awards (2009–2025).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Multiple Myeloma
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 4 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Blast Overpressure Longitudinal Study
Sponsor: Uniformed Services University of the Health Sciences
- Prokinetics and Body Surface Gastric Mapping in Dyspeptic Patients: Baseline and Treatment Effects
Sponsor: University of Auckland, New Zealand
- Body Surface Gastric Mapping Vs Gastric Emptying Scintigraphy on Clinical Management in Gastroparesis
Sponsor: University of Western Sydney
Industry payments
Updated 27 Aug 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year20253 payments
- Novo Nordisk IncProgram year20253 payments
- JAZZ PHARMACEUTICALS INC.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
62.6%Kinase inhibitor32.9%Jakafi100%Part D≥17 patientsSelective immunosuppressants22.6%Rezurock100%Part D≥12 patientsAnti-infectives
15.5%Short-acting sulfonamides15.5%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsMetabolism & gastrointestinal
12.3%Bile Acid12.3%Ursodiol100%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
2 NIH research awards on record, funded 2009–2025 per NIH RePORTER. The latest:
- Systematic identification of minor histocompatibility antigens to address GVHD
Dana-Farber Cancer Inst
FY2025$768,238R01HL157174 - Systematic identification of minor histocompatibility antigens to address GVHD
Dana-Farber Cancer Inst
FY2024$723,738R01HL157174 - Systematic identification of minor histocompatibility antigens to address GVHD
Dana-Farber Cancer Inst
FY2023$738,508R01HL157174
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.
Journal of clinical oncology
Clinical Trial2026 - User-Centered Development of the MyCare(2) Comprehensive Digital Support Platform for Caregivers of Individuals With Cancer.
JCO clinical cancer informatics
Article2026 - Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.
Clinical cancer research
Clinical Trial2023
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/vincent-ho-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
ashpublications.org/ashclinicalnews/news/2710/Pulling-Back-the-Curtain-Vincent-Ho-MD
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ashpublications.org ↗ - Other
blog.dana-farber.org/insight/2015/05/doctors-journey-out-of-saigon-inspires-clinical-career
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog.dana-farber.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Residency
Internal Medicine, Brigham and Women's Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Fellowship
Medical Oncology, Dana-Farber/Partners CancerCare
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Institute Physician
Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Member
Leukemia Program and Lymphoma/Myeloma Program, Dana-Farber/Harvard Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗
Awards & honors
honors on the public record- Top Doctor (Boston Magazine / Castle Connolly)
2026, also recognized in prior years including 2019 and 2020
2020verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Media & interviews
press, podcasts and appearances- "Pulling Back the Curtain: Vincent Ho, MD"
profile feature, ASH Clinical News (American Society of Hematology), May 2
2017provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ashpublications.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute